Magnesium Oxide Monohydrate for Nocturnal Leg Cramps (MgNLC)

This study has been terminated.
(Blinded interim analysis was presented to an independent data monitoring committee. Recommendation, submitted April 1, 2014, was early termination for futility.)
Sponsor:
Information provided by (Responsible Party):
Uzi Milman, Clalit Health Services
ClinicalTrials.gov Identifier:
NCT01709968
First received: October 17, 2012
Last updated: April 10, 2014
Last verified: April 2014

October 17, 2012
April 10, 2014
February 2013
October 2013   (final data collection date for primary outcome measure)
Number of documented episodes of NLC [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
The primary efficacy endpoint is the difference in the number of episodes of NLC documented in the NCSD, as compared between the MAGNOX 520® and the placebo treated individuals, during a treatment period of 4 weeks;
Same as current
Complete list of historical versions of study NCT01709968 on ClinicalTrials.gov Archive Site
  • Severity of documented episodes of NLC [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    The difference in the severity of episodes of NLC documented in the NCSD, as compared between the MAGNOX 520® and the placebo treated individuals, during a treatment period of 4 weeks;
  • Duration of documented episodes of NLC documented [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    The difference in the duration of episodes of NLC documented in the NCSD, as compared between the MAGNOX 520® and the placebo treated individuals, during a
  • Quality of life [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    The difference in the change in quality of life (measured by SF36 at enrolment and after the treatment period) between the MAGNOX 520® and the placebo treated individuals;
  • Quality of sleep [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    The difference in the change in quality of sleep (measured by PSQI at enrolment and after the treatment period) between the MAGNOX 520® and the placebo treated individuals;
Same as current
Not Provided
Not Provided
 
Magnesium Oxide Monohydrate for Nocturnal Leg Cramps
Magnesium Oxide Monohydrate for Nocturnal Leg Cramps (MgNLC); a Prospective, Randomized, Double Blind, Placebo Controlled Clinical Trial.

Nocturnal leg cramps (NLC) are painful, involuntary contractions of muscles occurring at rest, mostly at night. A Cochrane review on leg cramps in pregnancy showed some potential benefits in trials of magnesium. This is a single center, prospective, randomized, double blind, placebo controlled clinical trial that aims to investigate the effect of treatment with Magnox 520® (un-organic granular magnesium complex, composed of Magnesium Oxide & Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg++) on frequency and severity of NLC, quality of sleep and quality of life. Hypothesis: Magnox 520® may reduce the number and severity of NLC; an improvement in the quality of life and quality of sleep may ensue.

Ads in the local media and pharmacies will invite individuals afflicted by NLC to participate in the study. Each participating individual will undergo two weeks of eligibility screening followed by 4-week double-blind treatment. The number, severity and duration of NLC will be measured daily as documented in a designated, structured sleep dairy. Quality of life and quality of sleep will be assessed by SF-36 and PSQI questionnaires, respectively, to be completed twice - at enrollment and within one week of the end of the treatment period.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Nocturnal Leg Cramps
  • Quality of Life
Drug: MAGNOX 520®
Other Name: MAGNOX 520®
  • Experimental: MAGNOX 520®
    MAGNOX 520® (un-organic granular magnesium complex, composed of Magnesium Oxide & Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks.
    Intervention: Drug: MAGNOX 520®
  • Placebo Comparator: Similarly looking placebo.
    Similarly looking placebo. Oral administration once daily for 4 weeks.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
94
April 2014
October 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

Signed informed consent before any procedure or assessment is done. Age over 21 years old. Over 4 episodes of documented NLC during 2 weeks of eligibility screening (for the treatment phase).

Insured by Clalit Health Services (CHS). Hebrew speaking

Exclusion Criteria:

Pregnancy Currently taking Quinidine or Magnesium additive Renal failure - serum creatinine more than 2 mg/DL or estimated glomerular filtration rate (eGFR) less than 60 ml/min (the worst, ascertained by the participant electronic records in the last 6 months). If the result is near these limits (i.e. serum creatinin 1.5-2) a second analysis will be done near the study enrollment.

Major neurological disease- ALS, MS, Paraplegia or Quadriplegia.

Both
21 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT01709968
Com120009ctil
Yes
Uzi Milman, Clalit Health Services
Uzi Milman
Not Provided
Principal Investigator: Noga Maor Rougin, MD Clinical Research Unit, Clalit Health Services, Haifa and Western Galilee District, HAIFA, ISRAEL
Study Director: Uzi Milman, MD Clinical Research Unit, Clalit Health Services, Haifa and Western Galilee District, HAIFA, ISRAEL
Clalit Health Services
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP